News Releases
-
Blackhawk Growth to Complete Investment in Psychedelic & Wellness Company MindBio Therapeutics
1 September 2021
-
Blackhawk Growth Closes Investment in Psychedelic & Wellness Company MindBio Therapeutics
4 September 2021
-
Blackhawk Growth Subsidiary, MindBio Therapeutics Accelerates Phase 1 & Phase 2 Microdosing Clinical Trials
7 September 2021
-
Blackhawk Growth's MindBio Therapeutics Opens World Class Facility for the Pharmaceutical Industry
13 September 2021
-
Blackhawk Growth's MindBio Therapeutics Plans to Commercialize Intellectual Property Generated from the University of Auckland's Clinical Trial in Psychedelic Assisted Therapy in Advanced Stage Cancer Patients
16 September 2021
-
Blackhawk's MindBio Therapeutics Utilizes Trip Pharma to Bring Microdosing Trials to North America
23 September 2021
-
Blackhawk Growth's MindBio Therapeutics Signs Collaboration Agreement with Digital Mind Technology
29 September 2021
-
Blackhawk Growth's MindBio Therapeutics Successfully Progressed to the Second Half of Their Phase 1 Microdosing Clinical Trial
4 October 2021
-
Blackhawk Growth's MindBio Therapeutics Brings Digital Mental Health Technology to Psychedelics Clinical Trials
7 October 2021
-
Blackhawk Growth Appoints New Advisor To support Expansion Into Psychedelic and Mental Health Treatments
14 October 2021
Interviews & Media
-
Blackhawk Growth, an investment holding company, is acquiring MindBio Therapeutics
-
Emerging Treatments in Mental Health. Co-founder and Executive Director Justin Hanka discusses new treatments for mental health conditions.
-
Microdosing Clinical Research
-
Small Cap Investor Interview with Co-founder Justin Hanka
-
Talking Business Interview with Co-founder Justin Hanka
-
Why MindBio Therapeutics is investment in Microdosing clinical research
-
Justin Hanka Co-founder Presents at Microdose Psychedelic Capital
-
Clinical Trials and the University of Auckland
-
Psychedelic Titans
OPEN Psychedelic Titans story